189188-57-6
Tegaserod
CAS: 189188-57-6
Molecular Formula: C20H27N5O5
189188-57-6 - Names and Identifiers
| Name | Tegaserod |
| Synonyms | ZELMAC Tegaserod Tegaserode SDZ-HTF-919 TegaserodMalate TegastrodMaleate TEGASEROD MALEATE 2-[(5-METHOXY-1H-INDOL-3-YL)METHYLENE]-N-PENTYLHYDRAZINECARBOXIMIDAMIDE, MALEATE 2-[(5-methoxy-1h-indole-3-yl)methylene]-n-pentylcarbazimidamide hydrogen maleate 2-[(Z)-(5-methoxy-3H-indol-3-ylidene)methyl]-N'-pentylhydrazinecarboximidamide (2Z)-but-2-enedioate SDZ-HTF-919, Zelmac, 2-[(5-Methoxy-1H-indol-3-yl)methylene]-N-pentylhydrazinecarboximidamide, Maleate |
| CAS | 189188-57-6 |
| EINECS | 630-469-2 |
| InChI | InChI=1/C16H23N5O.C4H4O4/c1-3-4-5-8-18-16(17)21-20-11-12-10-19-15-7-6-13(22-2)9-14(12)15;5-3(6)1-2-4(7)8/h6-7,9-11,19H,3-5,8H2,1-2H3,(H3,17,18,21);1-2H,(H,5,6)(H,7,8)/b20-11+;2-1- |
189188-57-6 - Physico-chemical Properties
| Molecular Formula | C20H27N5O5 |
| Molar Mass | 417.46 |
| Melting Point | 180-183°C |
| Boling Point | 661.4°C at 760 mmHg |
| Flash Point | 353.8°C |
| Solubility | Acetonitrile (Slightly, Heated), DMSO (Slightly), Methanol (Sparingly) |
| Vapor Presure | 2.15E-18mmHg at 25°C |
| Appearance | powder |
| Color | white to beige |
| Storage Condition | 2-8°C |
| Physical and Chemical Properties | Melting point 180-183°C |
| In vitro study | Tegaserod was metabolized in human liver microsomes to O-desmethyl tegaserod at a low rate. Tegaserod had significant binding affinity for human recombinant 5-HT2A, 5-HT2B and 5-HT2C receptors (pK i =7.5, 8.4 and 7.0, respectively). Tegaserod (0.1-3 μM) inhibits 5-HT-mediated contraction of the rat isolated stomach fundus potently (pA 2 =8.3), consistent with 5-HT2B receptor antagonist activity. |
189188-57-6 - Preparation solution concentration reference
| 1mg | 5mg | 10mg | |
|---|---|---|---|
| 1 mM | 2.395 ml | 11.977 ml | 23.954 ml |
| 5 mM | 0.479 ml | 2.395 ml | 4.791 ml |
| 10 mM | 0.24 ml | 1.198 ml | 2.395 ml |
| 5 mM | 0.048 ml | 0.24 ml | 0.479 ml |
Last Update：2024-01-02 23:10:35
189188-57-6 - Reference Information
| application | tegazerol maleate in clinical application mainly: first, the therapeutic effect on IBS and functional constipation. Tagerol maleate is the first 5-HT4 receptor partial agonist to be used in the treatment of C -IBS. |
| pharmacological action | this product is a partial agonist of 5-HT receptor, which is closely bound to 5-HT4 receptor and shows high affinity. It has moderate affinity with 5-HT1 receptor, but cannot bind to 5-HT3 receptor, showing no affinity. Activation of 5-HT4 receptor can trigger the release of other neurotransmitters such as calcitonin-related gene peptide, stimulate intestinal peristaltic reflex and intestinal gland secretion, and inhibit visceral sensitivity. |
| toxicological research | In the experiment, the dose of drugs used by animals is far higher than the recommended dose for human clinical treatment. From the experiment of the effect of the drug and its main metabolites formed in the human body on the repolarization of rabbit isolated hearts, it is found that when the drug concentration is 0.5 μM, the change of Q-T is less than 5%; when the concentration is 50 μM (Human is about 500~1000 times the blood drug concentration produced by the recommended dose for human clinical oral administration), the Q-T change is 1.4%. In high-dose gastrointestinal effect experiments conducted in rats, mice and dogs, it was found that tegaserod maleate was non-toxic to the corresponding target organs; the thistle did not affect the immune system and reproductive ability; Carcinogenic experiments on rats and mice showed that the drug did not have carcinogenic ability. In vivo and in vitro experiments showed that there was no mutagenic ability and did not damage DNA. |
| biological activity | Tegaserod maleate are selective, partial agonists of 5-HT4 receptors and antagonists of 5-HT2B receptors. Tegaserod maleate shows a promoting effect in gastrointestinal tract. |
| Target | Value |
| Animal Model: | Female C57BLKS/J db/db mice. Three- to four-month-old female C57BL/6J mice. |
| Dosage: | 0.1, 0.5, 1.0, 2.0 mg/kg. 5, 10, 50, 100 μg/mL. |
| Administration: | IP 15 min prior to gastric loading. Alzet pumps into non-injured spinal cords. |
| Result: | Produced a dramatic decrease in the fraction of the meal remaining in the stomach for doses as low as 0.1 mg/kg (0.1 mg/kg). Accelerated gastric emptying, with a reduction of nearly 80% in the fraction remaining at 30 min (P < 0.0001) (0.1 mg/kg). Induced a significant decrease in the gastric emptying rate as the amount of the meal remaining at 30 min was significantly greater (2.0 mg/kg). Resulted in inhibition of tegaserod-induced increased gastric emptying (0.1 mg/kg). Showed a less intense astrogliosis within and in the vicinity of the compression lesion site when compared to vehicle-only-treated mice. Showed a smaller lesion area when compared to vehicle-onlytreated mice. Showed a higher staining intensity of 5-HT-immunoreactive axons 1 mm rostral, but not caudal to the lesion center as determined in cross-sections and quantification by ImageJ analysis. |
Last Update：2024-04-10 22:43:14
Supplier List
Spot supply
Product Name: Tegaserod Maleate Visit Supplier Webpage Request for quotationCAS: 189188-57-6
Tel: 18301782025
Email: 3008007409@qq.com
Mobile: 18021002903
QQ: 3008007409
Wechat: 18301782025
Spot supply
Product Name: Tegaserod Maleate Visit Supplier Webpage Request for quotationCAS: 189188-57-6
Tel: 18301782025
Email: 3008007409@qq.com
Mobile: 18021002903
QQ: 3008007409
Wechat: 18301782025
View History